Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Impaired T cell proliferation by ex vivo BET-inhibition impedes adoptive immunotherapy in a murine melanoma model.

Chee J, Wilson C, Buzzai A, Wylie B, Forbes CA, Booth M, Principe N, Foley B, Cruickshank MN, Waithman J.

Epigenetics. 2019 Aug 18. doi: 10.1080/15592294.2019.1656156. [Epub ahead of print]

PMID:
31423932
2.

Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens.

Wylie B, Chee J, Forbes CA, Booth M, Stone SR, Buzzai A, Abad A, Foley B, Cruickshank MN, Waithman J.

Oncoimmunology. 2019 Jun 3;8(8):1609874. doi: 10.1080/2162402X.2019.1609874. eCollection 2019.

3.

CD8+XCR1neg Dendritic Cells Express High Levels of Toll-Like Receptor 5 and a Unique Complement of Endocytic Receptors.

Wylie B, Read J, Buzzai AC, Wagner T, Troy N, Syn G, Stone SR, Foley B, Bosco A, Cruickshank MN, Waithman J.

Front Immunol. 2019 Jan 16;9:2990. doi: 10.3389/fimmu.2018.02990. eCollection 2018.

4.

Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.

Cheung LC, Cruickshank MN, Hughes AM, Singh S, Chua GA, Ford J, Ferrari E, Oommen J, Malinge S, Lock RB, Kees UR, Kotecha RS.

Haematologica. 2019 Jul;104(7):e300-e303. doi: 10.3324/haematol.2018.192906. Epub 2019 Jan 24. No abstract available.

5.

Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.

Wang E, Sorolla A, Cunningham PT, Bogdawa HM, Beck S, Golden E, Dewhurst RE, Florez L, Cruickshank MN, Hoffmann K, Hopkins RM, Kim J, Woo AJ, Watt PM, Blancafort P.

Oncogene. 2019 Jan;38(1):140-150. doi: 10.1038/s41388-018-0421-y. Epub 2018 Aug 3.

6.

Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.

Cruickshank MN, Ford J, Cheung LC, Heng J, Singh S, Wells J, Failes TW, Arndt GM, Smithers N, Prinjha RK, Anderson D, Carter KW, Gout AM, Lassmann T, O'Reilly J, Cole CH, Kotecha RS, Kees UR.

Leukemia. 2017 Jan;31(1):40-50. doi: 10.1038/leu.2016.165. Epub 2016 Jun 13.

7.

Analysis of tandem E-box motifs within human Complement receptor 2 (CR2/CD21) promoter reveals cell specific roles for RP58, E2A, USF and localized chromatin accessibility.

Cruickshank MN, Dods J, Taylor RL, Karimi M, Fenwick EJ, Quail EA, Rea AJ, Holers VM, Abraham LJ, Ulgiati D.

Int J Biochem Cell Biol. 2015 Jul;64:107-19. doi: 10.1016/j.biocel.2015.03.016. Epub 2015 Mar 27.

8.

Focused transcription from the human CR2/CD21 core promoter is regulated by synergistic activity of TATA and Initiator elements in mature B cells.

Taylor RL, Cruickshank MN, Karimi M, Ng HL, Quail E, Kaufman KM, Harley JB, Abraham LJ, Tsao BP, Boackle SA, Ulgiati D.

Cell Mol Immunol. 2016 Jan;13(1):119-31. doi: 10.1038/cmi.2014.138. Epub 2015 Feb 2.

9.

Analysis of epigenetic changes in survivors of preterm birth reveals the effect of gestational age and evidence for a long term legacy.

Cruickshank MN, Oshlack A, Theda C, Davis PG, Martino D, Sheehan P, Dai Y, Saffery R, Doyle LW, Craig JM.

Genome Med. 2013 Oct 18;5(10):96. doi: 10.1186/gm500. eCollection 2013.

10.

Longitudinal, genome-scale analysis of DNA methylation in twins from birth to 18 months of age reveals rapid epigenetic change in early life and pair-specific effects of discordance.

Martino D, Loke YJ, Gordon L, Ollikainen M, Cruickshank MN, Saffery R, Craig JM.

Genome Biol. 2013 May 22;14(5):R42. doi: 10.1186/gb-2013-14-5-r42.

11.

Going back to the future with Guthrie-powered epigenome-wide association studies.

Cruickshank MN, Pitt J, Craig JM.

Genome Med. 2012 Oct 30;4(10):83. doi: 10.1186/gm384. eCollection 2012.

12.

Neonatal DNA methylation profile in human twins is specified by a complex interplay between intrauterine environmental and genetic factors, subject to tissue-specific influence.

Gordon L, Joo JE, Powell JE, Ollikainen M, Novakovic B, Li X, Andronikos R, Cruickshank MN, Conneely KN, Smith AK, Alisch RS, Morley R, Visscher PM, Craig JM, Saffery R.

Genome Res. 2012 Aug;22(8):1395-406. doi: 10.1101/gr.136598.111. Epub 2012 Jul 16.

13.

Transcriptional effects of a lupus-associated polymorphism in the 5' untranslated region (UTR) of human complement receptor 2 (CR2/CD21).

Cruickshank MN, Karimi M, Mason RL, Fenwick E, Mercer T, Tsao BP, Boackle SA, Ulgiati D.

Mol Immunol. 2012 Oct;52(3-4):165-73. doi: 10.1016/j.molimm.2012.04.013. Epub 2012 Jun 4.

14.

The impact of histone post-translational modifications on developmental gene regulation.

Cruickshank MN, Besant P, Ulgiati D.

Amino Acids. 2010 Nov;39(5):1087-105. doi: 10.1007/s00726-010-0530-6. Epub 2010 Mar 5. Review.

PMID:
20204433
15.

The role of notch signaling in the development of a normal B-cell repertoire.

Cruickshank MN, Ulgiati D.

Immunol Cell Biol. 2010 Feb;88(2):117-24. doi: 10.1038/icb.2009.73. Epub 2009 Oct 6. Review.

PMID:
19806164
16.

Cell- and stage-specific chromatin structure across the Complement receptor 2 (CR2/CD21) promoter coincide with CBF1 and C/EBP-beta binding in B cells.

Cruickshank MN, Fenwick E, Karimi M, Abraham LJ, Ulgiati D.

Mol Immunol. 2009 Aug;46(13):2613-22. doi: 10.1016/j.molimm.2009.05.001. Epub 2009 May 31.

PMID:
19487031
17.

A critical assessment of the factors affecting reporter gene assays for promoter SNP function: a reassessment of -308 TNF polymorphism function using a novel integrated reporter system.

Karimi M, Goldie LC, Cruickshank MN, Moses EK, Abraham LJ.

Eur J Hum Genet. 2009 Nov;17(11):1454-62. doi: 10.1038/ejhg.2009.80. Epub 2009 May 27.

Supplemental Content

Loading ...
Support Center